{
    "Trade/Device Name(s)": [
        "George King Coumadin\u00ae Plasma"
    ],
    "Submitter Information": "George King Bio-Medical, Inc.",
    "510(k) Number": "K161316",
    "Predicate Device Reference 510(k) Number(s)": [
        "K971219"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GGN"
    ],
    "Summary Letter Date": "January 20, 2017",
    "Summary Letter Received Date": "January 24, 2017",
    "Submission Date": "February 10, 2017",
    "Regulation Number(s)": [
        "21 CFR 864.5425"
    ],
    "Regulation Name(s)": [
        "Multipurpose system for in vitro coagulation studies"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Prothrombin time (PT)",
        "INR"
    ],
    "Specimen Type(s)": [
        "Human plasma"
    ],
    "Specimen Container(s)": [
        "Plasmapheresis collection with 4.0% sodium citrate"
    ],
    "Instrument(s)/Platform(s)": [
        "ACL TOP 500",
        "ACL TOP 700"
    ],
    "Method(s)/Technology(ies)": [
        "Optical clot detection"
    ],
    "Methodologies": [
        "Clot-based coagulation monitoring"
    ],
    "Submission Type(s)": [
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for George King Coumadin\u00ae Plasma, an assayed control plasma for monitoring oral anticoagulant therapy using INR in clinical laboratories.",
    "Indications for Use Summary": "Intended for use as an assayed control plasma to monitor the accuracy and control of oral anticoagulant therapy using INR on an optical instrument with appropriate commercial reagents.",
    "fda_folder": "Hematology"
}